News Releases

Trump Administration to Review Fewer Health Plans for Drug Coverage; Patient Groups Concerned – Will Patients be Able to Access their Drugs?

Washington, DC – On the same day the Trump Administration issued a “market stabilization” rule that seeks to help the insurance companies stay in the individual market, CCIIO issued guidance to the states that announced it will conduct drug coverage reviews in fewer states.  Instead, CCIIO will rely more on the states to conduct these…

Read more

200 Patient Groups Urge Secretary Price to Safeguard Patient Protections in Reviewing Healthcare Reform

Washington, DC (February 13, 2017) – The I Am Essential coalition has sent a letter signed by 200 patient groups urging the recently confirmed Health and Human Services (HHS) Secretary Tom Price to maintain and enforce critical patient protections and prescription drug access when reviewing and suggesting changes to the Affordable Care Act (ACA). “While…

Read more

Patient Advocacy Groups Urge Administration to Enhance Patient Protections and Continue Progress to End Discrimination in the Exchanges

Washington, DC (October 6, 2016) – Today, the I Am Essential coalition submitted a comment letter signed by 153 advocacy groups on the Notice of Benefit and Payment Parameters for 2018 (NBPP) praising proposals that will create additional standardized plan options and utilize copays rather than co-insurance.

Read more

I Am Essential Coalition Urges Administration to End Discrimination in Health Insurance Exchanges

Washington, DC (August 25, 2016) – Yesterday, the I Am Essential coalition sent a letter to Health and Human Services (HHS) Secretary Sylvia Matthews Burwell to highlight on-going beneficiary concerns in implementation of the Affordable Care Act (ACA) ahead of the Administration’s final review of 2017 Qualified Health Plans (QHPs) and its release of the proposed 2018 Notice of Benefit and Payment Parameters (NBPP) Rule and Letter to Issuers.

Read more

Media Contact

Carl Schmid

(202) 669-8267

For Media Inquiries, please contact Carl Schmid of The AIDS Institute.